Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

The most popular content this past month included the release of the list of ACC 2021 late-breaking studies, the first AF patients treated with a new pulsed field ablation system, a blog on how the recently FDA cleared coronary lithotripsy balloon system may become a paradigm shift in the cath lab, and the development of engineered tissue valves that can grow with younger patients.

Feature | By Dave Fornell, Editor

April 1, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

April 01, 2021

The Medtronic Harmony Transcatheter Pulmonary Valve (TPV) System. It is first in the world non-surgical heart valve to treat pediatric and adult patients with a native or surgically-repaired right ventricular outflow tract (RVOT) to stop severe pulmonary valve regurgitation caused by congenital heart disease.

Feature | Structural Heart | By Dave Fornell, Editor

FDA Clears First Device to Treat Right Ventricular Outflow Tract Congenital Heart Disease

March 26, 2021 — Today, the U.S. Food and Drug Administration (FDA) cleared the Medtronic Harmony Transcatheter ...

March 26, 2021

The March April 2021 issue of DAIC, Diagnostic and Interventional Cardiology magazine, Dave Fornell is the editor.

Feature

The DAIC March-April 2021 Digital Edition

View the March-April 2021 digital edition of Diagnostic and Interventional Cardiology (DAIC) magazine, including links ...

March 26, 2021

Virtual tour views of a University of Colorado cath lab during a CTO procedure (top left), the new robotic EP lab at Banner Health (top right), a bi-plane EP/cath combo lab at Baylor Heart Hospital Dallas (bottom left, and an ECMO procedure at Tufts Medical Center cath lab. Photos by Dave Fornell

Feature

Virtual Tours of Cath and EP Labs

There is a lot of interest in how other hospitals organize and equip their cardiac cath labs and electrophysiology (EP) ...

March 25, 2021

Neonates and young pediatric patients with congenital heart disease have few options for implantable electrophysiology (EP) devices like pacemakers or ICDs.

News | Congenital Heart

Critical Need for Pediatric Electrophysiology Devices is Focus of Medical Device Competition

March 24, 2021 — Congenital heart disease (CHD) affects six out of 1,000 babies born in the U.S. each year and is often ...

March 24, 2021

PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

News | Heart Failure

100th Patient Implanted With Cordella Pulmonary Artery Pressure Sensor For Proactive, Remote Heart Failure Management

March 24, 2021 — Endotronix Inc., a digital health and medical technology company working on advancements in treating of ...

March 24, 2021

Videos | Structural Heart

VIDEO: PFO Closure Shows Continued Stroke Prevention Benefit at 5 Years

Interview with Scott E. Kasner, M.D., who served as the principle investigator for the Gore Cardioform REDUCE trial, and ...

March 23, 2021

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

Overview of Trials for Anticoagulation Therapy for COVID-19 Patients

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

March 22, 2021

Videos | Ventricular Assist Devices (VAD)

VIDEO: New LVAD Designed to Prevent Hemolysis and Clots

Surgeons at Penn State Heart and Vascular Institute were the second group in the nation to implant a newly-designed ...

March 22, 2021

University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. This can be implanted in pediatric patients with congenital heart diseas. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

News | Heart Valve Technology

Lab-created Heart Valves Can Grow With the Patient

March 18, 2020 — A groundbreaking new study led by University of Minnesota Twin Cities researchers from both the College ...

March 18, 2021

Boston Scientific's TheraSphere Y-90 Glass Microspheres enable selective internal radiation therapy (SIRT), or radioembolization, for hepatocellular carcinoma. This treats liver cancer with low toxicity using millions of microscopic glass beads containing radioactive yttrium (Y-90), delivered directly to liver tumors via catheter. The result in minimal radiation exposure to surrounding healthy tissue.

News | Interventional Radiology

FDA Clears Boston Scientific TheraSphere Y-90 Transcatheter Liver Embolization Microspheres

March 18, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's TheraSphere Y-90 Glass ...

March 18, 2021

A study from Washington University School of Medicine in St. Louis provides evidence that the coronavirus can invade and replicate inside heart muscle cells, causing cell death and interfering with heart muscle contraction. The image of engineered heart tissue shows human heart muscle cells (red) infected with COVID-19 (SARS-CoV-2) (green). Image by Lina Greenberg.

Feature | Coronavirus (COVID-19)

COVID-19 Can Kill Heart Cells and Interfere With Contraction

March 12, 2021 — Since early in the pandemic, COVID-19 has been associated with heart problems, including reduced ...

March 12, 2021

News | Cardiovascular Business

Cardinal Health Sells its Cordis Cardiology Business to Hellman & Friedman

March 12, 2021 — Cardinal Health today announced that it is selling its Cordis cardiology and endovascular business to ...

March 12, 2021

The Teleflex Manta large-bore vascular closure device can seal holes between 12 and 25 French.

Feature | Hemostasis Management | Dave Fornell, Editor

Large Bore Closure in Structural Heart Interventions

While many cardiac and vascular procedures have largely moved to minimally invasive techniques, the size of these ...

March 09, 2021

AMERICAN COLLEGE OF CARDIOLOGY (ACC) Late-breaking clinical trial study presentations at ACC.21. @ACC21 @ACC2021

Feature | ACC | Dave Fornell, Editor

ACC 2021 Late Breaking Cardiology Study Results

The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announced ...

May 18, 2021